Refine Search

Search Results -

Terms	Documents
6784155.pn. and caso$	1

Database: US Pre-Grant Publication Full-Text Database; US Patents Full-Text Database; US OCR Full-Text Database; EPO Abstracts Database; JPO Abstracts Database; Derwent World Patents Index; IBM Technical Disclosure Bulletins

Search: 4481191.pn. and caso$

Refine Search | Recall Text | Clear | Interrupt

Search History

DATE: Monday, December 06, 2004 Printable Copy Create Case

Set Name side by side	Query	Hit Count	Set Name result set
DB=PGPB,USPT,USOC,EPAB,JPAB,DWPI; PLUR=YES; OP=ADJ			
L14	6784155.pn. and caso$	1	L14
L13	L12 and caso$	1	L13
L12	6784155.pn. and blood	2	L12
L11	L10 and (heart or blood or cardio$ or arter$)	88	L11
L10	(casomorphin or caseomorphine)	114	L10
DB=USPT,USOC,EPAB,JPAB,DWPI; PLUR=YES; OP=ADJ			
L9	L7 same cardio$	2	L9
L8	L7 and cardio$	15	L8
L7	casomorphin	69	L7
L6	L5 and cardio$	0	L6
L5	caseomorphine	4	L5
L4	l1 and cardio$	15	L4
L3	l1 and cardiovascular	9	L3
L2	$casomorphin 9	0	L2

h e b b cg b e e ch

L1	$casomorphin	57	L1

END OF SEARCH HISTORY

h e b b cg b e e ch

L11: Entry 75 of 88 File: USPT Apr 14, 1998

DOCUMENT-IDENTIFIER: US 5739407 A
TITLE: Human .beta.-casein, process for producing it and use thereof

Brief Summary Text (10):
Soy-protein formulas, although different in carbohydrate and protein source, are similar in composition to cow's milk protein formulas following the American Academy of Pediatrics, Committee on Nutrition recommendations for nutrient levels in infant formulas. Differences include a slightly higher protein level and slightly lower carbohydrate content. The protein source is generally soy-protein; the fat is a blend of vegetable oils; and the source of carbohydrate is usually sucrose, corn syrup solids, or a mixture of both. However, the use of soy formulas tends to raise serum alkaline phosphatase and blood urea levels in infants in addition to causing the allergic and digestibility problems encountered with the use of bovine-based protein infant formulas.

Brief Summary Text (12):
.beta.-Casein is a phosphorylated protein which is present in milk of several species, including humans in which it is the major casein subunit. This protein--or its digested fragments--is believed to enhance calcium absorption by chelating calcium to its phosphorylated residues and thereby keeping it in an absorbable form. Human .beta.-casein is easily digested by newborn infants and the digestive products have been found to play an important role in the calcium uptake, and thus in the mineralization of the skeleton. A digestion product (.beta.-casomorphin) of human .beta.-casein has been found to have opioid activity and may be involved in the sleeping patterns of breast-fed infants.

Brief Summary Text (32):
The term "calcium-binding activity" denotes the capability of the polypeptide of the invention to bind calcium and may be determined by equilibrium dialysis or a similar technique. The term is to be understood in the sense that the polypeptide in question is capable of binding calcium by the same or substantially the same mechanism as human .beta.-casein; however, the term does not necessarily indicate that the binding is quantitatively the same, considering, inter alia, that the calcium binding capability is dependent on the degree of phosphorylation, which, on its side, may differ considerably dependent on the species in which the recombinant polypeptide is produced. The term "opioid activity" denotes the peptide's opiate-like effects and capability of the peptide to bind to opiate receptors (opiate receptor affinity). The "opioid activity" is determined as disclosed by Brantl, 1984 and Migliori-Samour et al. The term "ACE-inhibitory activity" denotes the capability of the peptide to inhibit the angiotensin converting enzyme (ACE) and has important indications for the treatment of heart disorders. The ACE-inhibitory effect is determined by use of a method as disclosed by Maruyama et al. and Kohmura et al.

Detailed Description Text (5):
Brantl, V. Novel opioid peptides derived from human .beta.-casein: Human .beta.-casomorphins. Eur. J. Pharmacol. 106, 213-214, 1984.

Other Reference Publication (10):
V. Brantl, "Novel Opioid Peptides Derived From Human Beta-Casein: Human Beta-

h e b b g eeeef c e g e g

Casomorphins", European Journal of Pharmacology; vol. 106, pp. 213-214 (1985).

Previous Doc Next Doc Go to Doc#

h e b b g e e e f c e g e g

analogue

<chemistry> A compound that is structurally similar to another.

(10 Jan 1998)

Previous: anallergic, anal membrane, analog, analog-digital conversion, analogous
Next: analogy, anal orifice, analphalipoproteinaemia, anal phase, anal pit

Cardiovascular effects of peptides related to the enkephalins and beta-casomorphin.

Wei ET, Lee A, Chang JK.

PMID: 7392801 [PubMed - indexed for MEDLINE]

h cb h g e e e fcg b e

1: Exp Clin Endocrinol. 1985 Apr;85(2):249-52. Related Articles, Li

Effect of beta-casomorphin and its analogue on serum prolactin the rat.

Nedvidkova J, Kasafirek E, Dlabac A, Felt V.

The effects of exogenous opioid peptides beta-casomorphin Tyr-Pro-Phe-Pro Gly-Pro-Ile and its analogue Tyr-Pro-Gly-Pro-Phe-Pro-Ile (analogue I) were found to increase prolactin level in plasma after intraperitoneal injection. Analogue I was more potent. This effect of beta-casomorphin and analogue I were blocked by an opioid antagonist, naloxone. These results indicate that tl exogenous opioid peptides (exorphins) may participate in the regulation of prolactin secretion. The similarity of analogue I with enkephalin structure wa discussed.

PMID: 4018163 [PubMed - indexed for MEDLINE]

h cb h g e e e fcg c e e e b b e

Refine Search

Search Results -

Terms	Documents
6784155.pn. and caso$	1

Database: US Pre-Grant Publication Full-Text Database; US Patents Full-Text Database; US OCR Full-Text Database; EPO Abstracts Database; JPO Abstracts Database; Derwent World Patents Index; IBM Technical Disclosure Bulletins

Search: 4481191.pn. and caso$

Refine Search | Recall Text | Clear | Interrupt

Search History

DATE: Monday, December 06, 2004 Printable Copy Create Case

Set Name side by side	Query	Hit Count	Set Name result set
DB=PGPB,USPT,USOC,EPAB,JPAB,DWPI; PLUR=YES; OP=ADJ			
L14	6784155.pn. and caso$	1	L14
L13	L12 and caso$	1	L13
L12	6784155.pn. and blood	2	L12
L11	L10 and (heart or blood or cardio$ or arter$)	88	L11
L10	(casomorphin or caseomorphine)	114	L10
DB=USPT,USOC,EPAB,JPAB,DWPI; PLUR=YES; OP=ADJ			
L9	L7 same cardio$	2	L9
L8	L7 and cardio$	15	L8
L7	casomorphin	69	L7
L6	L5 and cardio$	0	L6
L5	caseomorphine	4	L5
L4	l1 and cardio$	15	L4
L3	l1 and cardiovascular	9	L3
L2	$casomorphin 9	0	L2

h e b b cg b e e ch

d his full

(FILE 'HOME' ENTERED AT 18:06:38 ON 06 DEC 2004)

INDEX 'ADISCTI, ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, ANTE, AQUALINE, AQUASCI, BIOBUSINESS, BIOCOMMERCE, BIOENG, BIOSIS, BIOTECHABS, BIOTECHDS, BIOTECHNO, CABA, CANCERLIT, CAPLUS, CEABA-VTB, CEN, CIN, CONFSCI, CROPB, CROPU, DDFB, DDFU, DGENE, DISSABS, ...' ENTERED AT 18:06:48 ON 06 DEC 2004

SEA (CASOMORPHIN OR CASEOMORPHINE) (10W) (9 OR NINE) (P) (CARDIO? O

0* FILE ADISNEWS
0* FILE ANTE
0* FILE AQUALINE
0* FILE BIOCOMMERCE
0* FILE BIOENG
0* FILE BIOTECHABS
0* FILE BIOTECHDS
0* FILE BIOTECHNO
2 FILE CAPLUS
0* FILE CEABA-VTB
0* FILE CIN
0* FILE ESBIOBASE
0* FILE FEDRIP
0* FILE FOMAD
0* FILE FOREGE
2* FILE FROSTI
0* FILE FSTA
0* FILE KOSMET
0* FILE MEDICONF
0* FILE NTIS
0* FILE NUTRACEUT
0* FILE PASCAL
0* FILE PHARMAML
0* FILE WATER

L1 QUE (CASOMORPHIN OR CASEOMORPHINE) (10W) (9 OR NINE) (P) (CARDIO? OR HEART)

FILE 'CAPLUS, FROSTI' ENTERED AT 18:14:46 ON 06 DEC 2004

L2 4 SEA L1
L3 4 DUP REM L2 (0 DUPLICATES REMOVED)
D IBIB ABS L3 1-4
L4 1 SEA (CASOMORPHIN OR CASEOMORPHINE) (3W) (ANALOG?) (P) (HEART OR CARDIO?)
D IBIB ABS L4
L5 19 SEA (CASOMORPHIN OR CASEOMORPHINE) (P) (HEART OR CARDIO?)
L6 19 DUP REM L5 (0 DUPLICATES REMOVED)
D IBIB ABS L6 1-19

FILE 'ADISCTI, ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, ANTE, AQUALINE, AQUASCI, BIOBUSINESS, BIOCOMMERCE, BIOENG, BIOSIS, BIOTECHDS, BIOTECHNO, CABA, CANCERLIT, CAPLUS, CEABA-VTB, CEN, CIN, CONFSCI, CROPB, CROPU, DDFB, DGENE, DISSABS, DRUGB, DRUGMONOG2, ...' ENTERED AT 18:25:38 ON 06 DEC 2004

L7 4 SEA (CASOMORPHIN OR CASEOMORPHINE) (3W) (ANALOG?) (P) (CARDIO? OR HEART)
D IBIB ABS L7 1-4

FILE HOME

FILE STNINDEX

FILE CAPLUS

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:ssspta1651row

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS	1		Web Page URLs for STN Seminar Schedule - N. America
NEWS	2		"Ask CAS" for self-help around the clock
NEWS	3	SEP 01	INPADOC: New family current-awareness alert (SDI) available
NEWS	4	SEP 01	New pricing for the Save Answers for SciFinder Wizard within STN Express with Discover!
NEWS	5	SEP 01	New display format, HITSTR, available in WPIDS/WPINDEX/WPIX
NEWS	6	SEP 27	STANDARDS will no longer be available on STN
NEWS	7	SEP 27	SWETSCAN will no longer be available on STN
NEWS	8	OCT 28	KOREAPAT now available on STN
NEWS	9	NOV 18	Current-awareness alerts, saved answer sets, and current search transcripts to be affected by CERAB, COMPUAB, ELCOM, and SOLIDSTATE reloads
NEWS	10	NOV 30	PHAR reloaded with additional data
NEWS	11	DEC 01	LISA now available on STN

NEWS EXPRESS	OCTOBER 29 CURRENT WINDOWS VERSION IS V7.01A, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 11 AUGUST 2004
NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS INTER	General Internet Information
NEWS LOGIN	Welcome Banner and News Items
NEWS PHONE	Direct Dial and Telecommunication Network Access to STN
NEWS WWW	CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 18:06:38 ON 06 DEC 2004

=> index bioscience
FILE 'DRUGMONOG' ACCESS NOT AUTHORIZED

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

INDEX 'ADISCTI, ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, ANTE, AQUALINE, AQUASCI, BIOBUSINESS, BIOCOMMERCE, BIOENG, BIOSIS, BIOTECHABS, BIOTECHDS, BIOTECHNO, CABA, CANCERLIT, CAPLUS, CEABA-VTB, CEN, CIN, CONFSCI, CROPB, CROPU, DDFB, DDFU, DGENE, DISSABS, ...' ENTERED AT 18:06:48 ON 06 DEC 2004

```
75 FILES IN THE FILE LIST IN STNINDEX

Enter SET DETAIL ON to see search term postings or to view
search error messages that display as 0* with SET DETAIL OFF.

=> s (casomorphin or caseomorphine)(10w)(9 or nine)(P)(cardio? or heart)
          0*  FILE ADISNEWS
          0*  FILE ANTE
          0*  FILE AQUALINE
          0*  FILE BIOCOMMERCE
          0*  FILE BIOENG
          0*  FILE BIOTECHABS
          0*  FILE BIOTECHDS
          0*  FILE BIOTECHNO
          2   FILE CAPLUS
          0*  FILE CEABA-VTB
          0*  FILE CIN
  23 FILES SEARCHED...
          0*  FILE ESBIOBASE
  34 FILES SEARCHED...
          0*  FILE FEDRIP
          0*  FILE FOMAD
          0*  FILE FOREGE
          2*  FILE FROSTI
          0*  FILE FSTA
          0*  FILE KOSMET
          0*  FILE MEDICONF
          0*  FILE NTIS
          0*  FILE NUTRACEUT
          0*  FILE PASCAL
  55 FILES SEARCHED...
          0*  FILE PHARMAML
          0*  FILE WATER
  73 FILES SEARCHED...

   2 FILES HAVE ONE OR MORE ANSWERS,   75 FILES SEARCHED IN STNINDEX

L1   QUE (CASOMORPHIN OR CASEOMORPHINE)(10W)(9 OR NINE)(P)(CARDIO? OR HEART)

=> file caplus frosti
COST IN U.S. DOLLARS                                  SINCE FILE      TOTAL
                                                         ENTRY    SESSION
FULL ESTIMATED COST                                       7.41       7.62

FILE 'CAPLUS' ENTERED AT 18:14:46 ON 06 DEC 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'FROSTI' ENTERED AT 18:14:46 ON 06 DEC 2004
COPYRIGHT (C) 2004 Leatherhead Food Research Association

=> s l1
PROXIMITY OPERATOR LEVEL NOT CONSISTENT WITH
FIELD CODE - 'AND' OPERATOR ASSUMED 'NINE)(P)(CARDIO?'
L2            4 L1

=> dup rem l2
PROCESSING COMPLETED FOR L2
L3             4 DUP REM L2 (0 DUPLICATES REMOVED)

=> d ibib abs l3 1-4

L3   ANSWER 1 OF 4  CAPLUS  COPYRIGHT 2004 ACS on STN
```

ACCESSION NUMBER: 1990:179897 CAPLUS
DOCUMENT NUMBER: 112:179897
TITLE: Preparation of casomorphin analogs as cardiovascular agents
INVENTOR(S): Neubert, Klaus; Mentz, Peter; Barth, Alfred; Liebmann, Claus; Schrader, Uwe; Hartrodt, Bianka; Born, Ilona; Luecke, Lothar; Stoeckel, Christian; et al.
PATENT ASSIGNEE(S): VEB Fahlberg-List, Ger. Dem. Rep.
SOURCE: Ger. (East), 23 pp.
CODEN: GEXXA8
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DD 272227	A1	19891004	DD 1988-315831	19880517

PRIORITY APPLN. INFO.: DD 1988-315831 19880517
OTHER SOURCE(S): CASREACT 112:179897

AB **Cardioactive** prepns. containing **casomorphin** analogs at 10-**9**-10-7M were prepared Thus, H-Tyr-Pro-D-Phe-Pro-Gly-OH.HCl, prepared by the solution phase method, at 10-9M in guinea pig auricle increased cardiac performance (product of contractile amplitude and frequency) by 20%.

L3 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1987:44286 CAPLUS
DOCUMENT NUMBER: 106:44286
TITLE: Effects of β-casomorphin on 3H-ouabain binding to guinea pig heart membranes
AUTHOR(S): Liebmann, C.; Barth, A.; Neubert, K.; Mentz, P.; Hoffmann, S.
CORPORATE SOURCE: Dep. Biol., Friedrich-Schiller-Univ., Jena, DDR-4020, Ger. Dem. Rep.
SOURCE: Pharmazie (1986), 41(9), 670-1
CODEN: PHARAT; ISSN: 0031-7144
DOCUMENT TYPE: Journal
LANGUAGE: English

AB β- **Casomorphin** 5 (I) [72122-63-5] at low concns. (10-**9**-3 + 10-7 M) increased the binding of ouabain [630-60-4] to guinea pig cardiac cell membranes, but higher concns. (10-6-10-4 M) diminished the binding. Since I reputedly has a pos. inotropic effect on isolated hearts at low doses and a **cardiodepressive** action at higher doses, results are consistent with the concept that pos. inotropy is associated with an inhibition of the Na pump. Ouabain binding was not greatly altered by dihydromorphine [509-60-4] or D-Ala2-Leu5-enkephalin [64963-01-5], indicating that the effect of I was not mediated by μ- or δ-type opiate receptors.

L3 ANSWER 3 OF 4 FROSTI COPYRIGHT 2004 LFRA on STN
ACCESSION NUMBER: 583193 FROSTI
TITLE: Prophylactic dietary supplement based on milk.
INVENTOR: Elliott R.B.; Laugesen B.M.
PATENT ASSIGNEE: New Zealand Milk Institute Ltd
SOURCE: European Patent Application
PATENT INFORMATION: EP 1196047 A1
WO 2001000047 20010104
APPLICATION INFORMATION: 20000629
PRIORITY INFORMATION: New Zealand 19990629; 20000418
DOCUMENT TYPE: Patent
LANGUAGE: English
SUMMARY LANGUAGE: English

AB A fortified milk product is described, for use as a dietary supplement.

It contains cobalamin (vitamin V12), pyridoxine, folic acid, and betaine, with a casein fraction limited to Type 2 casein. The invention provides for manufacture of treated milk products and cereals. The supplement is intended to be used in control of diabetes and in reducing risk of **cardiovascular** disease. This may be achieved by treating an underlying deficiency of folate and other vitamins, thus controlling plasma homocysteine levels, and reducing intake of types A1 and B casein. High intake of these forms of casein is thought to be associated with diabetes. The immunological properties of beta-**casomorphin 9** are discussed. This is a relatively stable peptide digest fraction of A2 beta-casein.

L3 ANSWER 4 OF 4 FROSTI COPYRIGHT 2004 LFRA on STN
ACCESSION NUMBER: 545303 FROSTI
TITLE: Prophylactic dietary supplement based on milk.
INVENTOR: Elliott R.B.; Laugesen B.M.
PATENT ASSIGNEE: New Zealand Milk Institute Ltd
SOURCE: PCT Patent Application
PATENT INFORMATION: WO 2001000047 A1
APPLICATION INFORMATION: 20000629
PRIORITY INFORMATION: New Zealand 19990629; 20000418
DOCUMENT TYPE: Patent
LANGUAGE: English
SUMMARY LANGUAGE: English
AB A fortified milk product is described, for use as a dietary supplement. It contains cobalamin (vitamin V12), pyridoxine, folic acid, and betaine, with a casein fraction limited to Type 2 casein. The invention provides for manufacture of treated milk products and cereals. The supplement is intended to be used in control of diabetes and in reducing risk of **cardiovascular** disease. This may be achieved by treating an underlying deficiency of folate and other vitamins, thus controlling plasma homocysteine levels, and reducing intake of types A1 and B casein. High intake of these forms of casein is thought to be associated with diabetes. The immunological properties of beta-**casomorphin 9** are discussed. This is a relatively stable peptide digest fraction of A2 beta-casein.

=> d his full

(FILE 'HOME' ENTERED AT 18:06:38 ON 06 DEC 2004)

INDEX 'ADISCTI, ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, ANTE, AQUALINE, AQUASCI, BIOBUSINESS, BIOCOMMERCE, BIOENG, BIOSIS, BIOTECHABS, BIOTECHDS, BIOTECHNO, CABA, CANCERLIT, CAPLUS, CEABA-VTB, CEN, CIN, CONFSCI, CROPB, CROPU, DDFB, DDFU, DGENE, DISSABS, ...' ENTERED AT 18:06:48 ON 06 DEC 2004
SEA (CASOMORPHIN OR CASEOMORPHINE)(10W)(9 OR NINE)(P)(CARDIO? O

0* FILE ADISNEWS
0* FILE ANTE
0* FILE AQUALINE
0* FILE BIOCOMMERCE
0* FILE BIOENG
0* FILE BIOTECHABS
0* FILE BIOTECHDS
0* FILE BIOTECHNO
2 FILE CAPLUS
0* FILE CEABA-VTB
0* FILE CIN
0* FILE ESBIOBASE
0* FILE FEDRIP
0* FILE FOMAD
0* FILE FOREGE
2* FILE FROSTI

```
                0*  FILE FSTA
                0*  FILE KOSMET
                0*  FILE MEDICONF
                0*  FILE NTIS
                0*  FILE NUTRACEUT
                0*  FILE PASCAL
                0*  FILE PHARMAML
                0*  FILE WATER
L1               QUE (CASOMORPHIN OR CASEOMORPHINE)(10W)(9 OR NINE)(P)(CARDIO?
                 OR HEART)
                ---------

     FILE 'CAPLUS, FROSTI' ENTERED AT 18:14:46 ON 06 DEC 2004
L2             4 SEA L1
L3             4 DUP REM L2 (0 DUPLICATES REMOVED)
               D IBIB ABS L3 1-4


     FILE HOME

     FILE STNINDEX

     FILE CAPLUS

     Copyright of the articles to which records in this database refer is
     held by the publishers listed in the PUBLISHER (PB) field (available
     for records published or updated in Chemical Abstracts after December
     26, 1996), unless otherwise indicated in the original publications.
     The CA Lexicon is the copyrighted intellectual property of the
     American Chemical Society and is provided to assist you in searching
     databases on STN.  Any dissemination, distribution, copying, or storing
     of this information, without the prior written consent of CAS, is
     strictly prohibited.

     FILE COVERS 1907 - 6 Dec 2004  VOL 141 ISS 24
     FILE LAST UPDATED: 5 Dec 2004  (20041205/ED)

       This file contains CAS Registry Numbers for easy and accurate
       substance identification.


     FILE FROSTI
     FILE LAST UPDATED: 6 DEC 2004        <20041206/UP>
     FILE COVERS 1972 TO DATE.

     >>> SIMULTANEOUS LEFT AND RIGHT TRUNCATION IS AVAILABLE
         IN THE BASIC INDEX (/BI) FIELD  <<<
```

antiarrhythmic and coronary dilating actions, increase the expression of high affinity ouabain binding sites and modulate the functional properties of the myocardial beta-adrenoceptor G-protein complex. In the present study, the peptides (including 2-, 3- and 4-D-amino acid substituted beta-**casomorphin analogs** and partial amino acid sequences such as Pro-Gly and Tyr-Pro-Phe) protected isolated perfused guinea-pig **heart** and atria from various experimental injuries. **Cardioprotection** was possibly mediated by an influence on membrane integrity, receptor susceptibility and ion fluxes, and was especially effective in the depolarized myocardium. (congress abstract).

ABEX Experiments were performed with damaged preparations of auricles and isolated perfused hearts of guinea-pigs. Substances derived by substitution of beta-casomorphin by D-amino acids in the 2-, 3- or 4-positions exerted comparable cardiac effects. A similar efficacy was seen with compounds with partial amino acid sequences (e.g. Pro-Gly and Tyr-Pro-Phe). Experimentally induced cardiac injuries (provoked by hypoxia, calcium deficiency, potassium excess and PAF) provoked a significant reduction in cardiac performance up to 50-70% of the initial value. Under these conditions the investigated peptides markedly improved or even restored cardiac function. (NPH)

=>

>d l8

L8 ANSWER 1 OF 4 REGISTRY COPYRIGHT 2004 ACS on STN
RN 157173-37-0 REGISTRY
CN L-Asparagine, L-tyrosyl-L-prolyl-L-phenylalanyl-L-prolylglycyl-L-prolyl-L-isoleucyl-L-prolyl- (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN L-Asparagine, N2-[1-[N-[1-[N-[1-[N-(1-L-tyrosyl-L-prolyl)-L-phenylalanyl]-L-prolyl]glycyl]-L-prolyl]-L-isoleucyl]-L-prolyl]-
OTHER NAMES:
CN **Bovine [Pro8]-β-casomorphin-9**
FS PROTEIN SEQUENCE; STEREOSEARCH
MF C50 H68 N10 O12
SR CA
LC STN Files: CA, CAPLUS, CASREACT, TOXCENTER
DT.CA CAplus document type: Journal; Patent
RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); USES (Uses)
RL.NP Roles from non-patents: BIOL (Biological study); FORM (Formation, nonpreparative); PREP (Preparation); PROC (Process); PRP (Properties)

Absolute stereochemistry.



5 REFERENCES IN FILE CA (1907 TO DATE)
5 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=>

```
e.casomorphin-9/cn
E1              1      CASOMORPHIN, PRO-/CN
E2              1      CASOMORPHIN, PRO- (OX)/CN
E3              0 --> CASOMORPHIN-9/CN
E4              1      CASOMORPHINASE/CN
E5              1      CASORON/CN
E6              1      CASORON 133/CN
E7              1      CASORON G/CN
E8              1      CASOXIN 4/CN
E9              1      CASOXIN 5/CN
E10             1      CASOXIN 6/CN
E11             1      CASOXIN C/CN
E12             1      CASOXIN D/CN
```

=> d ibib abs l7 1-4

L7 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1990:179897 CAPLUS
DOCUMENT NUMBER: 112:179897
TITLE: Preparation of **casomorphin analogs** as **cardiovascular** agents
INVENTOR(S): Neubert, Klaus; Mentz, Peter; Barth, Alfred; Liebmann, Claus; Schrader, Uwe; Hartrodt, Bianka; Born, Ilona; Luecke, Lothar; Stoeckel, Christian; et al.
PATENT ASSIGNEE(S): VEB Fahlberg-List, Ger. Dem. Rep.
SOURCE: Ger. (East), 23 pp.
CODEN: GEXXA8
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DD 272227	A1	19891004	DD 1988-315831	19880517
PRIORITY APPLN. INFO.:			DD 1988-315831	19880517

OTHER SOURCE(S): CASREACT 112:179897
AB **Cardioactive** prepns. containing **casomorphin analogs** at 10-9-10-7M were prepared Thus, H-Tyr-Pro-D-Phe-Pro-Gly-OH.HCl, prepared by the solution phase method, at 10-9M in guinea pig auricle increased cardiac performance (product of contractile amplitude and frequency) by 20%.

L7 ANSWER 2 OF 4 DDFB COPYRIGHT 2004 THE THOMSON CORP on STN
ACCESSION NUMBER: 1980-36366 P A
TITLE: CARDIOVASCULAR EFFECTS OF PEPTIDES RELATED TO THE ENKEPHALINS AND BETA-CASOMORPHIN.
AUTHOR: WEI E T; LEE A; CHANG J K
LOCATION: BELMONT,CAL.,USA.
SOURCE: LIFE SCI. (26, NO.18, 1517-22, 1980)
LANGUAGE: English

L7 ANSWER 3 OF 4 DRUGB COPYRIGHT 2004 THE THOMSON CORP on STN
ACCESSION NUMBER: 1980-36366 P A
TITLE: CARDIOVASCULAR EFFECTS OF PEPTIDES RELATED TO THE ENKEPHALINS AND BETA-CASOMORPHIN.
AUTHOR: WEI E T; LEE A; CHANG J K
LOCATION: BELMONT,CAL.,USA.
SOURCE: LIFE SCI. (26, NO.18, 1517-22, 1980)
LANGUAGE: English

L7 ANSWER 4 OF 4 DRUGU COPYRIGHT 2004 THE THOMSON CORP on STN
ACCESSION NUMBER: 1992-15100 DRUGU P
TITLE: Effects of beta-Casomorphin and Related Peptides in Experimentally Induced Cardiac Injuries.
AUTHOR: Mentz P; Neubert K; Liebmann C; Hoffmann S; Barth A
LOCATION: Halle, Germany,West
SOURCE: Arch.Pharmacol. (344, Suppl. 2, R120, 1991)
CODEN: NSAPCC ISSN: 0028-1298
AVAIL. OF DOC.: Dept. of Pharmacology and Toxicology, Martin-Luther University Halle, Leninallee 4, 0-4020 Halle/S, Germany.
LANGUAGE: English
DOCUMENT TYPE: Journal
FIELD AVAIL.: AB; LA; CT; MPC
FILE SEGMENT: Literature
AN 1992-15100 DRUGU P
AB Beta-casomorphin and related peptides exert positive inotropic,

DERWENT-ACC-NO: 1990-076196

DERWENT-WEEK: 199011

TITLE: Cardioactive compsn. contg. casomorphine type peptide or derivs. - to strengthen heart beat, normalise cardiac rhythm and improve myocardial blood flow

INVENTOR: BARTH, A; BORN, I ; HARTRODT, B ; LIEBMANN, C D ; LUCKE, L ; MENTZ, P ; NEUBERT, K ; SCHRADER, U

PATENT-ASSIGNEE: VEB FAHLBERG-LIST M[VEFL]

PRIORITY-DATA: 1988DD-0315831 (May 17, 1988)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
DD 272227 A	October 4, 1989	N/A	021	N/A

APPLICATION-DATA:

PUB-NO	APPL-DESCRIPTOR	APPL-NO	APPL-DATE
DD 272227A	N/A	1988DD-0315831	May 17, 1988

INT-CL (IPC): A61K037/02

ABSTRACTED-PUB-NO: DD 272227A

BASIC-ABSTRACT:

Cardio-active compsn. contains as active ingredient a casomorphine-type peptide (I), or its deriv., at concn. of 1-100 nmoles/l or 1-1000 microg/kg.

USE/ADVANTAGE - (I) strengthen the heart beat, normalise cardiac rhythm and improve blood flow in the myocardium, so are useful in treatment of cardiac insufficiency and angina pectoris. They are well tolerated and can also be added (at 0.1-1%) to known cardiotonic, antiangina and antiarrhythmic compsns. to improve their activity. (I) are administered intravenously, intraperitoneally, orally or by infusion. The activity of (I) can be increased/prolonged by incorporation of D-amino acids; the cpds. are resistant to enzymatic breakdown; specified changes in structure can alter the activity profile, and modification of lipophilic and other physicochemical properties can improve transport and penetration properties.

CHOSEN-DRAWING: Dwg.0/0

TITLE-TERMS: CARDIOACTIVE COMPOSITION CONTAIN TYPE PEPTIDE DERIVATIVE STRENGTH HEART BEAT NORMALISE CARDIAC RHYTHM IMPROVE MYOCARDIUM BLOOD FLOW

DERWENT-CLASS: B04

CPI-CODES: B04-C01A; B12-F01; B12-F02;

CHEMICAL-CODES:
Chemical Indexing M1 *01*
Fragmentation Code
F012 F423 G010 G013 G100 H1 H100 H181 H4 H401
H441 H598 H8 J0 J011 J1 J111 J171 J311 J371
M210 M211 M271 M280 M281 M311 M312 M314 M320 M321
M331 M332 M333 M340 M342 M343 M349 M371 M381 M391
M423 M510 M520 M530 M531 M540 M620 M781 M903 P521
P522 P523 V902 V911 V921 V925
Registry Numbers
1327U 0502U

SECONDARY-ACC-NO:
CPI Secondary Accession Numbers: C1990-033359